Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 441,245 shares, an increase of 279.6% from the April 30th total of 116,241 shares. Based on an average trading volume of 3,204,496 shares, the short-interest ratio is currently 0.1 days. Approximately 8.6% of the company’s shares are short sold.

Institutional Trading of Shuttle Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SHPH. Geode Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $26,000. Boothbay Fund Management LLC purchased a new position in Shuttle Pharmaceuticals during the 4th quarter worth $37,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals during the 4th quarter worth $124,000. Finally, Connective Capital Management LLC purchased a new position in Shuttle Pharmaceuticals during the 3rd quarter worth $357,000. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Trading Down 5.6%

SHPH stock traded down $0.03 on Friday, hitting $0.51. The company’s stock had a trading volume of 112,491 shares, compared to its average volume of 2,101,171. The firm has a 50 day moving average of $0.79 and a two-hundred day moving average of $1.31. Shuttle Pharmaceuticals has a 1 year low of $0.50 and a 1 year high of $6.19. The stock has a market cap of $2.97 million, a price-to-earnings ratio of -0.11 and a beta of 0.38.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.43) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, May 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .